Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children

详细信息    查看全文

• 作者：Pakpoom Janewongwirot^a ; Thanyawee Puthanakit^a ; ^b ; ^{thanyawee.p@chula.ac.th" class="auth_mail" title="E-mail the corresponding author} ; Suvaporn Anugulruengkitt^a ; ^b ; Watsamon Jantarabenjakul^a ; ^b ; Chayapa Phasomsap^a ; ^b ; Sompong Chumket^a ; ^b ; Sutee Yoksan^c ; Chitsanu Pancharoen^a ; ^b
• 关键词：Japanese encephalitis vaccine ; Children ; Immunogenicity ; Safety
• 刊名：Vaccine
• 出版年：2016
• 出版时间：17 October 2016
• 年：2016
• 卷：34
• 期：44
• 页码：5279-5283
• 全文大小：494 K

文摘

Japanese Encephalitis chimeric virus vaccine (JE-CV) and SA14-14-2 vaccine are live-attenuated JE vaccines produced from the same virus strain. Data on interchangeability is limited.

Objectives

To evaluate the immunogenicity and safety of JE-CV booster after primary vaccination with SA14-14-2 vaccine.

Methods

This study was an open-label clinical trial in Thai children who had received a primary SA14-14-2 vaccination at 12–24 months before enrollment (ClinicalTrials.gov NCT02602652). JE-CV was administered. A 50% plaque reduction neutralization test (PRNT₅₀) against three virus strains; JE-CV, SA-14-14-2 and wild-type JE virus was measured before and 28-days post vaccination. The laboratory was performed at PRNT₅₀ titers ⩾10 (1/dil) were considered seroprotective against JE. Geometric mean titer (GMT) of PRNT₅₀ was calculated. Adverse events were observed for 28 days.

Results

From March 2014 to June 2015, 50 children (64% male) were enrolled. Mean age and duration after primary vaccination was 26.9 (SD 4.6) and 12.8 (SD 2.7) months, respectively. The proportion of participants who had PRNT₅₀pre and post-booster vaccination were 92% and 96% against JE-CV virus, 56% and 98% against SA-14-14-2 strain and 70% and 98% against wild-type JE virus, respectively. Solicited injection site reactions including erythema, pain and swelling occurred in 18%, 10% and 4% of subjects, respectively. Four children (8%) had fever (⩾37.7 Celsius). Eight children (16%) had adverse events, which were not related to the vaccine.

Conclusions

AJE-CV booster dose is highly immunogenic and safe among children who previously received SA14-14-2 vaccine.